Biotest AG: Biotest acquires further plasmapheresis centre
Biotest AG / Miscellaneous
Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.
----------------------------------------------------------------------
Biotest acquires further plasmapheresis centre
- Station in the USA with annual collection capacity of 40,000 litres
- Number of centres operated by Biotest rises to 21
- Independence and resources secured through high level of
self-sufficiency
Dreieich, 11 February 2009. Biotest has acquired a further plasmapheresis
centre in the USA. US subsidiary Biotest Pharmaceuticals Corporation (BPC)
took over the collection station of a competitor, located in Santa Fe in
the state of New Mexico. The facility has just been built and is due to
open shortly. Once established, the centre is expected to generate up to
40,000 litres of plasma from donor blood each year.
With the acquisition, the number of plasma centres operated by Biotest
worldwide increases to 21, 11 of which are located in the USA and ten in
Europe. Since the US centres are also licensed by the European authorities,
US plasma can be produced in Europe, too.
With the expansion of its own capacities to obtain plasma, Biotest is
reacting to the ongoing high demand for the end products produced from this
raw material. At present, more than 40% of blood plasma processed by
Biotest is supplied by the company’s own collection stations. With a high
level of self-sufficiency, Biotest is safeguarding against fluctuations in
price and supply in the global market and can guarantee adequate provision
of high quality plasma at all times.
Human blood plasma is the raw material required to produce plasma proteins,
which are used in the treatment of various diseases of the immune system
and the hematopoietic system as well as in emergency medicine. Biotest is
among the six largest global manufacturers of plasma proteins.
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and asset
situation of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
deviation of actual developments from expected developments. The
forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
About Biotest
Biotest is a company that researches and manufactures pharmaceutical,
biotherapeutic and diagnostic products and has specialised in the areas of
application of immunology and haematology. In its Plasma Protein segment,
Biotest develops and markets immunoglobulins, coagulation factors and
albumins based on human blood plasma. These are used for diseases of the
immune and haematopoietic systems. In the Biotherapeutic segment, Biotest
researches into the clinical development of monoclonal antibodies,
including in the indications of rheumatoid arthritis and leukaemia. The
Microbiological Monitoring segment comprises reagents and systems for
microbiology, which are primarily used in hygiene monitoring. Products
manufactured by the Medical Diagnostic segment are used, for example, in
blood transfusions and transplants. Biotest has around 1,950 employees
worldwide. The shares of Biotest AG are listed in the SDAX on the Frankfurt
stock exchange.
Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.de
Dr. Michael Ramroth,
Tel: +49 (0) 6103 801-520,
e-mail: michael_ramroth@biotest.de
Fax: +49 (0) 6103 801-347
WKN, ISIN ordinary share: 522720, DE0005227201
WKN, ISIN preference share: 522723, DE0005227235
Listed: Prime Standard/official trading
Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart
11.02.2009 Financial News transmitted by DGAP
----------------------------------------------------------------------
Language: English
Issuer: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Deutschland
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227201, DE0005227235
WKN: 522720, 522723
Indices: SDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------------
